Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer - sprookjes - yvandenbroek - TriplyDB

Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer

Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer

http://www.wikidata.org/entity/Q36641362

about

Thalidomide analogues as anticancer drugs The treatment of advanced renal cell cancer with high-dose oral thalidomide A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a Gynecologic Oncology Group study.Phase 2 trial of combination thalidomide plus temozolomide in patients with metastatic malignant melanoma: Southwest Oncology Group S0508.Antiangiogenic gene therapy with soluble VEGFR-1, -2, and -3 reduces the growth of solid human ovarian carcinoma in mice The current status of interferon-alpha treatment in advanced renal cancer.Effects of thalidomide on angiogenesis and tumor growth and metastasis of human hepatocellular carcinoma in nude mice.Novel therapies for renal cell carcinoma.Fibroblast growth factors: biology, function, and application for tissue regeneration.Results of a multicenter, randomized, double-blind, dose-evaluating phase 2/3 study of lenalidomide in the treatment of metastatic malignant melanoma.Thalidomide and lenalidomide: Mechanism-based potential drug combinations.Thalidomide as an anti-cancer agent.Thalidomide: an old drug with new clinical applications.Angiogenesis, lymphangiogenesis, and melanoma metastasis.Thalidomide: a new anticancer drug?Novel therapeutic agents under investigation for malignant melanoma.Thalidomide in dermatology: revisited.Evolving immunotherapeutic strategies in bladder and renal cancer Molecular biological design of novel antineoplastic therapies.Adjuvant therapy for malignant melanoma.Novel agents in epithelial ovarian cancer.Treatment of recurrent or metastatic renal cell carcinoma.Therapeutic renaissance of thalidomide in the treatment of haematological malignancies.Novel agents in development for the treatment of melanoma.Thalidomide: dermatological indications, mechanisms of action and side-effects.Immunomodulatory drugs.Randomized trial of adjuvant thalidomide versus observation in patients with completely resected high-risk renal cell carcinoma.A pilot study of antiangiogenic therapy with bevacizumab and thalidomide in patients with metastatic renal cell carcinoma Where is VEGF in the body? A meta-analysis of VEGF distribution in cancer.Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers.New approaches in metastatic melanoma: biological and molecular targeted therapies.The FGF family: biology, pathophysiology and therapy Dermatologic therapeutics: thalidomide. A practical guide.Inflammatory cytokine tumor necrosis factor alpha confers precancerous phenotype in an organoid model of normal human ovarian surface epithelial cells.Current systemic therapy for metastatic melanoma.Thalidomide: an old drug with new action.Metronomic chemotherapy for cancer treatment: a decade of clinical studies.Antiangiogenic agents in advanced, persistent or recurrent endometrial cancer: a novel treatment option.Acetamides: chemotherapeutic agents for inflammation-associated cancers.Thalidomide inhibits lipopolysaccharide-induced tumor necrosis factor-alpha production via down-regulation of MyD88 expression.

P2860

Q24670383-C19D2F9A-7EEF-4A73-94AD-BA3FC7FDB037 Q28361231-DB1CAD17-5EB9-47FE-9A3D-F1BF0038AEA3 Q30442540-D98112B6-7C5D-4688-A867-A03EEEC3EB5E Q33611998-55D553EA-E924-4A42-B8CC-2C9A5569352D Q33713224-B0B67309-8B3F-4906-B2D6-95945D2B5455 Q34249614-D9854E54-6BAE-4212-A4AE-5EAB76444230 Q34382640-738FDEA7-C19C-467C-B3A9-19652FCF5355 Q34481460-DB1C9578-DD08-47E3-A362-6F57E478FB6D Q34591107-939071E9-84AC-431E-AC64-BFE3C47392F4 Q34611491-6209DF91-8CF2-42B4-B0C9-74A97BAB4BEB Q34775475-D933A816-C26A-4568-96AE-1226F328EB47 Q34778074-B0548BFA-833A-4119-9C8B-848EBD4C43B7 Q34798767-54E438F4-A7E5-4F65-9636-3E67480C9120 Q35146591-3D4291D8-4D45-4AE8-8C7D-8FD23550E331 Q35164773-578775A8-0BA6-4E1D-B40D-5AB8BEB35950 Q35207632-78C93785-979F-48A1-B71D-0E8FD7DCDC0C Q35215252-A0C01D67-75BC-4193-83BA-32C9DA1A9468 Q35519671-15594836-8DF4-40F4-A900-5BC2B2A37E21 Q35790781-CECCD037-22AF-441A-9530-982E28C43DA4 Q35918453-87D0519E-B96C-42F1-A721-04423EC63D59 Q35968752-E3B45786-5D3D-4625-B859-19AD43319A4C Q35987766-A2CB861E-1DD1-4C54-A13D-F8E00DA53900 Q36171864-62524FCC-DA37-4F9A-B937-316068EACADF Q36196484-1869C079-E300-4CEB-A4FD-ADB0976E9DF4 Q36222128-5859E7C7-FC2D-421F-A85E-D64D31CFD468 Q36321396-7D48460C-A4B6-4589-B2A6-3EDCFF6BFC22 Q36491239-ED4FF194-345D-4071-89CA-4F196B082997 Q36509683-AE3A77D2-A1DB-4AD9-AF3D-33898A82A681 Q36611325-FC5CBE82-C00A-4E1C-8972-DAB6A71BF954 Q36696902-44E2E5AD-3C47-435B-8FCC-82B28509900D Q36817127-A5002A37-6F31-43C6-AC15-13E91D73BBF0 Q36933339-F6A9E9DC-317D-4CCA-A263-E44BA1F67937 Q36986014-D30E9708-E9F2-43E8-8C80-FBD170C7D9F6 Q37200457-6F583E24-58EA-456A-9C89-90583378B62B Q37483961-B1133702-BAFC-4AB6-B724-18257B35116F Q37974744-8539321A-22CA-4D72-8A45-BE9038CCA966 Q38087885-0BD8C2AF-7E47-4760-9853-123E6D65F453 Q38114478-DC027D88-191D-4E0E-B432-90B123E51B78 Q38551665-CA1FF55F-2DAD-43E1-BA35-01B2FA4566DA Q39886089-D54BA9CB-713D-4E41-9B11-64C423F0ED34

P2860

Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer

http://www.wikidata.org/entity/Q36641362

description

2000 nî lūn-bûn

@nan

2000年の論文

@ja

2000年論文

@yue

2000年論文

@zh-hant

2000年論文

@zh-hk

2000年論文

@zh-mo

2000年論文

@zh-tw

2000年论文

@wuu

2000年论文

@zh

2000年论文

@zh-cn

name

Continuous low dose Thalidomid ...... ell, ovarian and breast cancer

@ast

Continuous low dose Thalidomid ...... ell, ovarian and breast cancer

@en

type

label

Continuous low dose Thalidomid ...... ell, ovarian and breast cancer

@ast

Continuous low dose Thalidomid ...... ell, ovarian and breast cancer

@en

prefLabel

Continuous low dose Thalidomid ...... ell, ovarian and breast cancer

@ast

Continuous low dose Thalidomid ...... ell, ovarian and breast cancer

@en

P1433

Q36641362-F9073C39-3C2E-448F-B7E0-25A95420C1AE

P1476

Q36641362-58BFABF2-0694-41F4-9DA5-6F2A9204FFFC

P2093

Q36641362-3286C519-4308-44E2-AD24-0412CD7ACE43

Q36641362-33102E6D-2E06-4231-A164-600A68F36BB4

Q36641362-4E627719-5C54-4566-AAD7-6286FD8FB2EA

Q36641362-576692A1-7246-4218-B954-E8DD9CE66E6C

Q36641362-72D56931-6E4B-456D-8180-89C5334570FC

Q36641362-9AA1ADE9-F286-4405-AA23-DB810E2D32EC

Q36641362-BC2970D8-0F78-48B1-9845-0B41E0353641

Q36641362-E34037FA-0820-4676-8C22-0CC99C2C5C64

Q36641362-E69EB293-5133-4AAE-9386-82AB348913E4

Q36641362-EC80460C-B57B-460E-86CE-DC3561B32983

P2860

Q36641362-160DBFE5-1F01-43DC-BA1A-473E57F8D457

Q36641362-187C3502-DFC3-4209-87BE-35A711B417ED

Q36641362-34A548F2-C805-4138-B192-D621CA061C57

Q36641362-39AE5857-7703-4EE4-BCF0-31792AC40CE9

Q36641362-3BF9C80A-EC06-4DE9-972F-90B4C2898C3D

Q36641362-3FC81851-4CBC-47DB-8EDF-FC65A5F5E0B5

Q36641362-41403E43-5AE8-4E80-8784-6D180819627C

Q36641362-430C1824-73E5-433D-9748-CA7A005193D3

Q36641362-49640DC7-E6AE-4EF5-9AAF-7847AE297E14

Q36641362-56167576-BC9A-4256-803F-03470E7F113D

P2888

Q36641362-7EA7488A-9A60-4031-8DBE-74EB77BE081A

P304

Q36641362-12EB82FF-CDE5-4373-94B2-42656405B401

P31

Q36641362-4C19B692-EA59-4E09-AB7D-4AFF90BC40CB

P356

Q36641362-1070D76B-E3AA-4278-9382-EDFC8A167C84

P407

Q36641362-60F3BD9A-AA84-4168-9406-E1DB69AC242A

P433

Q36641362-2F274655-2FA0-4AC8-B8F4-C419F87F9366

P478

Q36641362-92C245EA-0464-49C1-9F73-94D5EB9BB705

P577

Q36641362-1F2A53A7-4348-4AA3-A306-3968DE9E0A59

P5875

Q36641362-E76093B6-1A01-45A6-95DC-8AB323275D77

P6179

Q36641362-FC98B128-54AB-4A24-8C70-34A62E8EAE90

P698

Q36641362-01C6C832-DA5F-4358-A8E7-A0ECAAFDC741

P921

Q36641362-3E30CD4D-315D-43D0-AB73-CF5CC7117005

P932

Q36641362-10099003-3A25-45C9-AA36-6FD421710926

P356

P1433

British Journal of Cancer

P1476

Continuous low dose Thalidomid ...... ell, ovarian and breast cancer

@en

P2093

Ahern R

http://www.w3.org/2001/XMLSchema#string

Boshoff C

http://www.w3.org/2001/XMLSchema#string

Eisen T

http://www.w3.org/2001/XMLSchema#string

Gore ME

http://www.w3.org/2001/XMLSchema#string

Johnston SR

http://www.w3.org/2001/XMLSchema#string

Mak I

http://www.w3.org/2001/XMLSchema#string

Pyle L

http://www.w3.org/2001/XMLSchema#string

Sapunar F

http://www.w3.org/2001/XMLSchema#string

Smith IE

http://www.w3.org/2001/XMLSchema#string

Vaughan MM

http://www.w3.org/2001/XMLSchema#string

P2860

Thalidomide is an inhibitor of angiogenesis

Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth

Angiogenesis in cancer, vascular, rheumatoid and other disease

Reporting results of cancer treatment

Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma.

Intratumor microvessel density as a prognostic factor in cancer

Dual role of tumor necrosis factor-alpha in angiogenesis

Separable growth and migration factors for large-cell lymphoma cells secreted by microvascular endothelial cells derived from target organs for metastasis.

Guideline for the clinical use and dispensing of thalidomide

Loss of ovarian function promotes angiogenesis in human ovarian carcinoma

P2888

P304

812-817

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1054/BJOC.1999.1004

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

82

http://www.w3.org/2001/XMLSchema#string

P577

2000-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

12582964

http://www.w3.org/2001/XMLSchema#string

P6179

1046792955

http://www.w3.org/2001/XMLSchema#string

P698

10732751

http://www.w3.org/2001/XMLSchema#string

P921

P932

2374399

http://www.w3.org/2001/XMLSchema#string